.Avidity Biosciences satisfied financiers with period 1/2 information in Duchenne muscular dystrophy...
.Actinogen Medical's cortisol blocker has skipped the major endpoint of a period 2 research study in...
.Antibody-drug conjugates (ADCs) have gone to the center of many a billion-dollar biobuck licensing ...
.Asset manager TPG, which has sustained biotechs including Sionna Therapeutics and also Santa Clam A...
.Merck & Co.'s TIGIT plan has endured another trouble. Months after shuttering a period 3 cancer ...
.After a year determined by pipe cuts, the shift of its CEO and also discharges, Exscientia is going...
.Cullinan Therapy was impressed sufficient along with Port BioMed's bispecific immune system reactor...
.In this particular week's episode of "The Leading Pipe," our experts're diving in to Strong Biotech...
.The confetti is still soaring coming from Eli Lilly's gathering celebrating the commendation of Alz...
.Welcome to today's Chutes & Ladders, our roundup of notable management hirings, shootings and al...